License Agreements - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended	9 Months Ended	12 Months Ended	0 Months Ended		12 Months Ended	1 Months Ended		9 Months Ended	1 Months Ended
	Jan. 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014 Upfront payment [Member]	Sep. 30, 2013 Upfront payment [Member]	Sep. 30, 2014 Upfront payment [Member]	Sep. 30, 2013 Upfront payment [Member]	Jan. 31, 2014 Allegro stockholders [Member]	Oct. 05, 2011 Grupo Ferrer Internacional, S.A. [Member]	Mar. 31, 2012 Grupo Ferrer Internacional, S.A. [Member]	Sep. 30, 2014 Grupo Ferrer Internacional, S.A. [Member]	Dec. 31, 2013 Grupo Ferrer Internacional, S.A. [Member]	Mar. 15, 2012 Grupo Ferrer Internacional, S.A. [Member] Private Placement [Member]	Oct. 05, 2011 Grupo Ferrer Internacional, S.A. [Member] Allegro stockholders [Member]	Dec. 31, 2013 Grupo Ferrer Internacional, S.A. [Member] Allegro stockholders [Member]	Jun. 30, 2014 Teva Pharmaceuticals USA, Inc. [Member]	May 31, 2013 Teva Pharmaceuticals USA, Inc. [Member]	Sep. 30, 2014 Teva Pharmaceuticals USA, Inc. [Member]	May 31, 2013 Teva Pharmaceuticals USA, Inc. [Member] Allegro stockholders [Member]
License Agreements [Line Items]
Upfront cash received under collaborative arrangement											$ 10,000,000								$ 40,000,000
Payments to former stockholders under collaborative arrangement										250,000						5,000,000	312,500				10,000,000
Eligible receipt of additional milestone payments											51,000,000			48,000,000					195,000,000
License agreement contractual terms													Until the later of the last to expire patent covering ADASUVE in such country or 12 years after first commercial sale.
License agreement term period													12 years
Aggregate purchase price												241,936
Purchase of common stock, value												3,000,000
Common stock price, per share												$ 12.40
Premium on the fair value from sale of stock, classified as deferred revenue															1,452,000
Estimated performance period of agreement													4 years
Revenue under agreement		364,000	1,978,000	2,461,000	46,236,000	364,000	729,000	1,457,000	2,186,000
Deferred revenue		3,643,000		3,643,000
Upfront cash received under collaborative arrangement	1,000,000													1,250,000
Sale of notes backed by royalty and milestone payments																				45,000,000
Guarantee of notes																				The notes have no recourse to us, other than to our equity interest in our wholly-owned subsidiary, and we did not guarantee the notes.
Aggregate term loan advances																			25,000,000
Number of years from effective date to receive note advances																			2 years
Expected volatility rate				87.00%															70.00%
Estimated debt yield				0.00%															15.00%
Fair value of right-to-borrow note																			2,800,000
Interest expense amortization period				5 years															2 years
Borrowing under loan agreement				50,830,000	10,000,000													25,000,000
Eligible receipt of additional payments																				$ 195,000,000